Muenster, NW, DE 

Overview

Rudiger Liersch practices practicing medicine in Muenster, Germany.

Their clinical expertise encompasses Marginal Zone Lymphoma (MZL), Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), and Leukemia.

They are actively involved in clinical research, co-authoring 29 peer reviewed articles and participating in 3 clinical trials.

Locations

Muenster, NW, Germany
Other Locations
Erlangen, BY, Germany
Koeln, NW, Germany
Dortmund, NW, Germany

Frequently Asked Questions about Rudiger Liersch

Is Rudiger Liersch a top-rated expert for Marginal Zone Lymphoma (MZL)?

MediFind is an objective health platform that identifies experts based on real-world data. Rudiger Liersch is classified as an Experienced expert for Marginal Zone Lymphoma (MZL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Rudiger Liersch participate in research or clinical trials?

Yes. Rudiger Liersch has published 29 articles and abstracts on conditions like Marginal Zone Lymphoma (MZL). You can view a list of Rudiger Liersch's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Liersch's expertise for a condition
ConditionClose
        View All 10 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile